Lunit Presents Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology

Lunit's research showcases how AI-driven biomarkers can improve clinical workflows, uncover spatial features of the tumor microenvironment, and enable integrated analysis to support treatment decisions.

Apr. 17, 2026 at 7:21pm

Got story updates? Submit your updates here. ›

A highly structured abstract painting featuring sweeping geometric arcs, concentric cellular structures, and precise biological spirals in muted tones, conceptually representing the complex patterns and order within the tumor microenvironment as analyzed by Lunit's AI-driven biomarker research.Lunit's AI-powered insights into the spatial dynamics of the tumor microenvironment are unlocking new possibilities for precision oncology.San Diego Today

Lunit, a leading provider of AI for cancer diagnostics and precision oncology, presented six studies at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The presentations highlighted Lunit's advancements in AI-driven biomarker development, tumor microenvironment (TME) analysis, and real-world clinical applicability, including collaborations with global partners like Agilent Technologies.

Why it matters

Lunit's research demonstrates how AI-powered solutions are translating into real-world clinical impact, enhancing precision, deepening understanding of tumor biology, and increasingly supporting treatment decision-making in cancer care. The findings underscore the growing complexity of biomarker assessment, where both tumor characteristics and immune context need to be considered, highlighting the potential role of AI in this process.

The details

Key studies presented by Lunit at AACR 2026 include: 1) Analyzing over 25,000 non-small cell lung cancer (NSCLC) samples to reveal a spatial immune exclusion pattern linked to c-MET overexpression, 2) Demonstrating that AI-quantified HER2 expression is strongly associated with treatment response in HER2-positive metastatic colorectal cancer patients treated with tucatinib plus trastuzumab, and 3) Showing that tumor-infiltrating lymphocyte (TIL) density independently predicts progression-free survival, with low stromal TIL levels correlating with no treatment response.

  • The AACR Annual Meeting 2026 took place from April 17 to 22 in San Diego, California.
  • Lunit presented its research findings during various poster sessions throughout the conference.

The players

Lunit

A leading provider of AI for cancer diagnostics and precision oncology, headquartered in Seoul, South Korea.

Agilent Technologies

A global partner that collaborated with Lunit on several of the presented studies.

Ajou University Medical Center

A research institution that collaborated with Lunit and Agilent Technologies on a study analyzing over 25,000 non-small cell lung cancer samples.

Brandon Suh

The CEO of Lunit.

David Rimm

A researcher at the Yale University School of Medicine who collaborated with Lunit on a study analyzing tumor-infiltrating lymphocytes in non-small cell lung cancer.

Got photos? Submit your photos here. ›

What they’re saying

“Our AACR presentations reflect how AI is increasingly translating into real-world clinical impact”

— Brandon Suh, CEO of Lunit

What’s next

Lunit will continue to showcase its latest research and AI-powered solutions in cancer diagnostics and therapeutics at its booth #2248 during the AACR 2026 conference.

The takeaway

Lunit's research at AACR 2026 highlights the growing role of AI in enhancing precision oncology, deepening our understanding of tumor biology, and supporting more informed treatment decision-making. As the complexity of biomarker assessment increases, AI-driven tools are proving invaluable in integrating tumor characteristics and immune context to optimize patient care.